Integra LifeSciences (NASDAQ:IART) Receives "Sell (D)" Rating from Weiss Ratings

Integra LifeSciences (NASDAQ:IART - Get Free Report)'s stock had its "sell (d)" rating reiterated by research analysts at Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.

Separately, Citigroup reaffirmed a "sell" rating and issued a $12.00 price target (up previously from $10.00) on shares of Integra LifeSciences in a report on Tuesday. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and four have given a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Reduce" and a consensus price target of $16.83.

Integra LifeSciences Stock Up 2.6%

Shares of NASDAQ:IART opened at $14.81 on Wednesday. The company has a current ratio of 1.23, a quick ratio of 0.73 and a debt-to-equity ratio of 1.18. Integra LifeSciences has a 12 month low of $11.06 and a 12 month high of $27.13. The company has a 50-day moving average price of $14.29 and a 200 day moving average price of $14.50. The company has a market cap of $1.15 billion, a price-to-earnings ratio of -2.27 and a beta of 1.21.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The life sciences company reported $0.45 EPS for the quarter, beating analysts' consensus estimates of $0.43 by $0.02. Integra LifeSciences had a negative net margin of 30.87% and a positive return on equity of 12.15%. The firm had revenue of $415.61 million during the quarter, compared to the consensus estimate of $395.06 million. During the same quarter last year, the firm earned $0.63 EPS. The firm's revenue for the quarter was down .6% compared to the same quarter last year. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. As a group, equities research analysts predict that Integra LifeSciences will post 2.45 earnings per share for the current year.

Institutional Trading of Integra LifeSciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Arizona State Retirement System increased its position in shares of Integra LifeSciences by 4.2% during the first quarter. Arizona State Retirement System now owns 19,894 shares of the life sciences company's stock worth $437,000 after acquiring an additional 795 shares during the period. Wedge Capital Management L L P NC increased its position in shares of Integra LifeSciences by 1.2% during the second quarter. Wedge Capital Management L L P NC now owns 70,114 shares of the life sciences company's stock worth $860,000 after acquiring an additional 801 shares during the period. GAMMA Investing LLC increased its position in shares of Integra LifeSciences by 55.3% during the third quarter. GAMMA Investing LLC now owns 2,565 shares of the life sciences company's stock worth $37,000 after acquiring an additional 913 shares during the period. Osaic Holdings Inc. increased its position in shares of Integra LifeSciences by 36.6% during the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company's stock worth $51,000 after acquiring an additional 1,104 shares during the period. Finally, Envestnet Asset Management Inc. increased its position in shares of Integra LifeSciences by 4.6% during the first quarter. Envestnet Asset Management Inc. now owns 27,527 shares of the life sciences company's stock worth $605,000 after acquiring an additional 1,204 shares during the period. 84.78% of the stock is owned by hedge funds and other institutional investors.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.